Pfizer's Q3 results are due on Nov. 4, with analysts eyeing $16.6B in sales and EPS of 66 cents as investors weigh the ...

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $30.0 for Pfizer during the past quarter. Looking at the volume ...

Viking Therapeutics is mispriced due to the successful but misunderstood clinical results of their oral GLP-1 treatment. Read ...

Discover top large-cap value stocks using YCharts & Ben Graham Formula. Find high-yield dividend picks for October 2024.

CorMedix CRMD is expected to report its third-quarter 2025 earnings results soon. The Zacks Consensus Estimate for sales and ...

Eli Lilly LLY has been on an acquisition spree since the beginning of this year to bolster its pipeline, which should drive ...

Merck MRK will report its third-quarter 2025 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for ...

In the competitive world of small-cap biotechnology, CorMedix CRMD and Theravance Biopharma TBPH stand out as two companies ...

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

Pfizer has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s ...

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

All of this has weighed on stock performance, leaving the shares down almost 50% over the past three years. Considering this, ...